This clinical trial is focused on studying the effects of a medication called metformin on a condition known as Myotonic Dystrophy Type 1, also referred to as Steinert’s Disease. This is a genetic disorder that affects muscle function, leading to muscle weakness and other symptoms. The study will compare the effects of metformin with a placebo to see if metformin can improve muscle function in people with this condition.

The purpose of the study is to evaluate how well metformin works in improving muscle function in patients with Myotonic Dystrophy Type 1. Participants in the study will be randomly assigned to receive either metformin or a placebo. The study will last for about 12 months, during which participants will have regular check-ups to monitor their muscle function and overall health. The study will also assess the safety of metformin by keeping track of any serious side effects that may occur during the treatment period.

Throughout the study, various aspects of muscle function will be measured, including walking ability, hand-grip strength, and other physical capabilities. The study will also look at how metformin affects heart and lung function, as well as the overall quality of life for participants. By the end of the study, researchers hope to determine whether metformin can be a beneficial treatment for improving muscle function in people with Myotonic Dystrophy Type 1.